NEW YORK (GenomeWeb) – Intellia Therapeutics has filed a preliminary prospectus for an initial public offering worth up to $120 million. The firm has separately announced a licensing and collaboration agreement with Regeneron Pharmaceuticals for in vivo therapeutic development with a focus on liver diseases that is potentially worth billions.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.